- Home
- Cellular Signaling / Musculoskeletal Research
Cellular Signaling / Musculoskeletal Research
The Recovery, Growth & Performance category is the largest in our research compound library — 14 peptides covering two distinct research areas: tissue repair and regeneration research, and growth hormone axis signaling research.
Research Peptides — Third-Party Tested
Tissue repair compounds include BPC-157, TB-500, their pre-combined blend, ARA-290, KPV, LL-37, and SS-31 — each studied for distinct cellular signaling mechanisms involved in wound repair, cell migration, angiogenesis, and anti-inflammatory pathways. These compounds are among the most referenced in the preclinical tissue repair literature.
Growth hormone axis compounds include CJC/IPA, Tesamorelin, Tesa/IPA blend, Hexarelin, IGF-1 LR3, L-Carnitine, and B12 — representing GHRH analogs, ghrelin receptor agonists, and downstream IGF-1 pathway compounds. All 14 peptides in this category are independently third-party tested to greater than 99% purity with batch-specific Certificate of Analysis documentation.
BPC-157 & TB-500 — Most Studied Tissue Repair Research Peptides
BPC-157 and TB-500 are the two most referenced peptides in preclinical tissue repair literature. Their complementary mechanisms have made them a standard combination in laboratory tissue regeneration research — BPC-157 initiates local vascular repair and angiogenesis while TB-500 amplifies systemic cell migration and structural remodeling. Understanding each compound individually helps researchers design protocols targeting specific repair mechanisms.
BPC-157 — 10mg
Body Protection Compound — Gastric Pentadecapeptide
BPC-157 is a synthetic 15-amino acid gastric pentadecapeptide fragment derived from the human gastric juice protein BPC. In preclinical research, it is among the most studied peptides for angiogenesis promotion, local tissue repair initiation, and growth factor modulation at injury sites. Its stability in gastric acid environments and ability to cross biological barriers has made it a model compound in gastrointestinal and musculoskeletal tissue repair research.
BPC-157 research has examined its interaction with multiple growth factor pathways including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and nitric oxide synthase (NOS) systems. In tendon and ligament repair research models, BPC-157 has demonstrated dose-dependent effects on collagen organization and tenocyte proliferation. In gastrointestinal research, it has been studied extensively for its cytoprotective signaling in gastric mucosal tissue.
Key Research Areas:
- Angiogenesis signaling
- Tendon and musculoskeletal repair research
- Gastrointestinal cytoprotective research
- Growth factor receptor interaction studies
Available:
- BPC-157 10mg
TB-500 (Thymosin Beta-4 Fragment) — 10mg
Synthetic Thymosin Beta-4 Fragment
TB-500 is a synthetic fragment of Thymosin Beta-4 — a 43-amino acid protein involved in actin regulation and cellular migration. TB-500 corresponds to the actin-binding domain of TB-4, which is responsible for its primary biological activity in research models. In preclinical studies, TB-500 promotes broad systemic cell migration, soft-tissue and muscle regeneration, and new blood vessel formation through mechanisms distinct from those of BPC-157.
Research with TB-500 has explored its role in activating resident progenitor cell populations in tissue repair models. In dermal wound models, Thymosin Beta-4 promoted hair follicle stem cell migration and differentiation, accelerating wound closure. TB-500 research has also examined cardiovascular repair signaling, with published studies investigating its potential in cardiac tissue research models. Its systemic distribution pattern makes it complementary to the more locally-acting BPC-157 in multi-compound tissue repair research designs.
Key Research Areas:
- Systemic cell migration
- Soft tissue and muscle regeneration models
- Cardiovascular tissue research
- Actin regulation and cytoskeletal studies
Available:
- TB-500 10mg
BPC/TB Blend — Dual Pathway Tissue Research Compound
BPC/TB Blend — 10mg / 10mg
BPC-157 + TB-500 Pre-Combined
The BPC/TB blend combines BPC-157 and TB-500 in a single pre-combined research compound at 10mg each. In laboratory tissue repair research, these two peptides act through complementary mechanisms — BPC-157 initiates local angiogenesis and growth factor modulation at injury sites while TB-500 amplifies systemic cell migration and structural remodeling downstream of the initial repair cascade.
Pre-combining them in a single compound streamlines research protocols studying both mechanisms simultaneously. Researchers studying multi-phase tissue regeneration models, or investigating the synergistic effects of combined angiogenic and cell migration signaling, will find the BPC/TB blend an efficient research tool. Each component is independently verified for purity before blending; the batch-specific COA covers both compounds.
Research Advantage:
- Dual-pathway tissue repair in a single compound — BPC-157 initiates local angiogenesis, TB-500 amplifies systemic cell migration and remodeling. Combined effect mirrors multi-phase natural tissue repair cascade.
Available:
- BPC/TB Blend 10mg/10mg
ARA-290, KPV, LL-37 & SS-31 — Supporting Tissue Repair Research Compounds
Beyond BPC-157 and TB-500, this category includes four additional tissue and cellular repair research compounds targeting distinct mechanisms in inflammatory signaling, antimicrobial research, and mitochondrial biology.
ARA-290 — 10mg
Erythropoietin-Derived Innate Repair Receptor Agonist
ARA-290 is an 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). It selectively targets the innate repair receptor (IRR) — a heterodimer distinct from the classical EPO receptor — without stimulating erythropoiesis. In laboratory research, ARA-290 is studied for neuroprotective signaling pathways, cellular repair mechanisms, and anti-inflammatory pathway modulation. Its selectivity for IRR over the classical EPO receptor makes it a clean research tool for studying innate repair biology without erythropoietic confounds.
Available:
- ARA-290 10mg
KPV — 10mg
Alpha-MSH C-Terminal Tripeptide
KPV is the C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH). It retains the anti-inflammatory signaling properties of the parent molecule while being significantly smaller and more stable. KPV is studied for its interaction with melanocortin receptors (MC1R, MC3R, MC4R) in anti-inflammatory research models. Research applications include gut epithelial signaling studies, inflammatory pathway modulation, and melanocortin receptor interaction research.
Available:
- KPV 10mg
LL-37 — 5mg
Human Cathelicidin-Derived Antimicrobial Peptide
LL-37 is the only known human cathelicidin-derived antimicrobial peptide. It is produced by cleavage of the hCAP-18 precursor protein and plays roles in innate immune defense, wound healing signaling, and inflammation modulation. In laboratory research, LL-37 is studied for its antimicrobial mechanism of action, innate immune signaling, angiogenic properties in wound healing models, and interactions with toll-like receptor (TLR) pathways. Its broad biological activity makes it a research compound of interest across immunology and wound repair research disciplines.
Available:
- LL-37 5mg
SS-31 (Elamipretide) — 50mg
Mitochondria-Targeting Tetrapeptide
SS-31 (also known as Elamipretide or MTP-131) is a synthetic cell-permeable tetrapeptide that selectively targets the inner mitochondrial membrane. It is studied for its interaction with cardiolipin — a phospholipid critical to mitochondrial inner membrane integrity and electron transport chain function. Research with SS-31 focuses on mitochondrial membrane potential, oxidative phosphorylation efficiency, and intracellular energy regulation in cellular stress models. It represents a mechanistically distinct approach to cellular repair research compared to receptor-mediated peptides.
Note: SS-31 URL on the site is currently /product/§-31/ — recommend fixing to /product/ss-31-50mg/ for SEO purposes before publishing content.
Available:
- SS-31 50mg
Growth Hormone Secretagogue & IGF-1 Research Peptides
Growth hormone axis research compounds fall into three mechanistic classes. GHRH analogs (Tesamorelin, CJC-1295 No DAC) mimic growth hormone-releasing hormone and stimulate pituitary GH secretion through the GHRH receptor on somatotroph cells. GHRPs — Growth Hormone Releasing Peptides (Hexarelin, Ipamorelin in CJC/IPA) — independently stimulate GH secretion through the ghrelin receptor (GHS-R1a). IGF-1 LR3 acts downstream of GH — directly on IGF-1 receptors in target tissues — bypassing pituitary GH secretion entirely.
The GH–IGF-1 axis is a critical pathway for muscle, bone, and connective tissue research. Compounds targeting this axis at different points allow researchers to study pituitary GH pulsatility, downstream IGF-1 signaling, and the differential effects of GHRH vs ghrelin receptor activation on GH pulse dynamics and composition.
CJC/IPA, Tesamorelin & Tesa/IPA — GHRH + GHRP Research Compounds
CJC/IPA Blend — 5mg / 5mg
CJC-1295 No DAC + Ipamorelin — Dual GH Secretagogue Blend
The CJC/IPA blend combines CJC-1295 No DAC (a modified GHRH analog) with Ipamorelin (a selective GHS-R1a ghrelin receptor agonist) in a single pre-combined research compound. This combination is considered the reference dual-pathway GH secretagogue blend in peptide research — CJC-1295 activates the pituitary GHRH receptor stimulating physiological GH pulse release, while Ipamorelin activates the independent ghrelin receptor pathway for complementary GH secretion. Together they provide synergistic somatotropic axis stimulation.
Ipamorelin is notable for its selectivity — it produces GH release with minimal off-target effects on cortisol or prolactin compared to earlier GHRPs like GHRP-2 or GHRP-6. This selectivity makes CJC/IPA a methodologically clean research tool for studying GH axis biology without hormonal noise from prolactin or cortisol confounds.
Available:
- CJC/IPA 5mg/5mg
Tesamorelin (TESA) — 10mg
GHRH Analog — Highest Clinical Evidence
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), currently the highest-evidence GHRH analog in clinical use. It received FDA approval (as Egrifta) for HIV-associated lipodystrophy treatment — making it the only GHRH analog with Phase III clinical trial data supporting its mechanism of action. In research settings, Tesamorelin is studied for pulsatile GH release stimulation, downstream IGF-1 axis effects, and GHRH receptor binding kinetics in controlled laboratory models.
Available:
- Tesamorelin 10mg (TESA)
Tesa/IPA Blend — 12mg / 6mg
Tesamorelin + Ipamorelin Pre-Combined
The Tesa/IPA blend combines Tesamorelin (clinical-grade GHRH analog) and Ipamorelin (selective GHRP) in a single pre-combined research compound. This combination pairs the highest-evidence GHRH analog with the most selective GHRP currently available, providing dual-pathway GH secretagogue research capability. The 12mg Tesamorelin to 6mg Ipamorelin ratio reflects standard research protocol ratios used to achieve synergistic pituitary stimulation through complementary receptor pathways.
Available:
- Tesa/IPA 12mg/6mg
Hexarelin, IGF-1 LR3, L-Carnitine & B12 — Supporting GH Axis Compounds
Hexarelin — 5mg
Potent GHRP — Ghrelin Receptor Agonist
Available:
- Hexarelin 5mg
IGF-1 LR3 — 1mg
Modified IGF-1 Analog — Extended Half-Life
IGF-1 LR3 (Long Arg3 IGF-1) is a modified analog of insulin-like growth factor-1 with an extended half-life of approximately 20-30 hours compared to minutes for native IGF-1. The LR3 modification reduces binding protein affinity, increasing bioavailability in research models. IGF-1 LR3 acts directly on IGF-1 receptors in target tissues — bypassing pituitary GH production entirely. It is used in research studying downstream somatotropic pathway biology, anabolic signaling in muscle and bone tissue, and receptor-mediated IGF-1 effects independent of GH secretion.
Available:
- IGF-1 LR3 1mg
L-Carnitine — 1200mg
Amino Acid Derivative — Mitochondrial Fatty Acid Transport
L-Carnitine is a naturally occurring amino acid derivative synthesized from lysine and methionine. In research settings, it is studied for its role as the obligate carrier for long-chain fatty acids across the inner mitochondrial membrane — a critical step in beta-oxidation and cellular energy production. L-Carnitine research spans metabolic pathway analysis, mitochondrial function assessment, and lipid oxidation studies in muscle and hepatic tissue models. It is often included in multi-compound research protocols alongside GH secretagogue peptides.
Available:
- L-Carnitine 1200mg
B12 (Methylcobalamin) — 10mg
Research-Grade Methylcobalamin
B12 (Methylcobalamin) is a research-grade cobalamin compound. Methylcobalamin is the bioactive form of Vitamin B12 and a critical cofactor in methylation reactions. In research settings, it is studied for its role in neurological function (myelin sheath synthesis), one-carbon metabolism and methylation pathway research, and cellular energy metabolism as a cofactor in mitochondrial reactions. It is commonly used as a foundational compound in multi-compound research protocols alongside recovery and performance peptides.
Available:
- B12 10mg
Why Purity Matters in Recovery & Growth Research
Recovery and performance research requires compounds of verifiable purity. Impure peptides introduce variables that compromise receptor binding studies, signaling cascade analysis, and dose-response experiments. A BPC-157 compound tested at 85% purity is not the same research tool as one verified at 99.4% — the 14.6% difference could represent degradation products, synthetic byproducts, or unidentified contaminants that confound research results.
Every recovery, growth and performance research peptide sold by Midnight Sun Peptides is independently tested by an accredited third-party laboratory. Our testing includes:
- HPLC Purity Analysis — confirms the exact purity percentage of the target compound in each lot
- Mass Spectrometry Identity Confirmation — verifies the compound is correctly identified, not just pure
- Batch-Specific COA — the actual laboratory test report for your specific production lot, with batch number, purity percentage, MW confirmation, and lab name
Batch-specific COAs are available on every individual product page. Unlike generic documentation that shows a single historical test, our COAs correspond to the exact production batch you receive — providing full traceability for your research records.
Frequently Asked Questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a synthetic gastric pentadecapeptide that promotes angiogenesis and local tissue repair initiation — it drives local vascular repair and growth factor modulation at injury sites. TB-500 is a synthetic fragment of Thymosin Beta-4 that supports systemic cell migration and broader tissue remodeling. They act through complementary mechanisms — BPC-157 initiates the local repair cascade while TB-500 amplifies systemic cellular migration and structural remodeling. Many researchers study them in combination (BPC/TB blend) because their combined activity mirrors the multi-phase nature of natural tissue repair: vascular repair precedes cellular differentiation and matrix reconstruction.
What are GH secretagogue research peptides?
GH secretagogue peptides stimulate growth hormone release from the pituitary gland through two main pathways. GHRH analogs (Tesamorelin, CJC-1295 No DAC) mimic growth hormone-releasing hormone and act on the GHRH receptor on pituitary somatotroph cells to stimulate physiological GH pulse release. GHRPs — Growth Hormone Releasing Peptides (Hexarelin, Ipamorelin in CJC/IPA) — independently activate the ghrelin receptor (GHS-R1a). CJC/IPA and Tesa/IPA blends combine both pathways. IGF-1 LR3 acts downstream of GH — directly on IGF-1 receptors in target tissues — bypassing pituitary GH secretion entirely.
What is ARA-290 and what is it studied for?
ARA-290 is an 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). It selectively targets the innate repair receptor (IRR) — a heterodimer distinct from the classical EPO receptor — without stimulating erythropoiesis (red blood cell production). In laboratory research, ARA-290 is studied for its role in neuroprotective signaling pathways, cellular repair mechanisms, and anti-inflammatory pathway modulation in controlled research models. Its selectivity for IRR over the classical EPO receptor makes it a clean research tool for studying innate repair biology.
What purity level are these research peptides?
All recovery, growth, and performance research peptides are independently verified at greater than 99% purity using HPLC analysis and mass spectrometry identity confirmation. Testing is performed by an accredited third-party laboratory — not in-house. Batch-specific Certificates of Analysis showing the actual test results for your production lot are available on every individual product page.
Are these peptides approved for human use?
No. All products in this category are sold strictly for laboratory and controlled scientific research purposes only (Research Use Only — RUO). Note: Tesamorelin (sold commercially as Egrifta) is FDA-approved as a pharmaceutical product for HIV-associated lipodystrophy, but our research-grade Tesamorelin is not that product and is not approved for any human use. All compounds on this page are for laboratory research only and should not be administered to humans or animals under any circumstances.
Research Use Only Disclaimer:
All products on this page are sold strictly for laboratory and controlled scientific research purposes only. These compounds are not approved by the FDA or any regulatory authority for human or veterinary use. They are not intended for consumption, therapeutic application, or administration to humans or animals. All use must remain within qualified laboratory research settings.
